Comparison of magnetic resonance imaging to ultrasound for prostate sizing.


Journal

The Canadian journal of urology
ISSN: 1195-9479
Titre abrégé: Can J Urol
Pays: Canada
ID NLM: 9515842

Informations de publication

Date de publication:
12 2021
Historique:
entrez: 13 12 2021
pubmed: 14 12 2021
medline: 9 4 2022
Statut: ppublish

Résumé

To compare pelvic ultrasound (PUS) and transrectal ultrasound (TRUS) to magnetic resonance imaging (MRI) in the estimation of prostate size. After IRB approval, we performed a single-center, retrospective study of 91 patients who had prostate sizing between August, 2013 and June, 2017. Correlation, reliability, and agreement between PUS, TRUS, and MRI were calculated through the Pearson coefficient, intraclass correlation coefficient, and Bland-Altman analysis, respectively. Data was stratified by prostate size, body mass index, and time between imaging acquisition. A total of 91 patients underwent all three imaging methods. Median age was 64, median body mass index (BMI) was 27 kg/m2, and median PSA value prior to PUS was 7.1 ng/mL. Pearson coefficient for MRI versus TRUS and MRI versus PUS was 0.90 and 0.87, respectively. Intraclass correlation coefficient was 0.90 (0.87-0.93) comparing all three modalities. BA analysis for MRI versus TRUS and MRI versus PUS showed that for prostates ≤ 50 cc, greater than 79% of the data fell within limits of agreement. Percentages decreased with increasing prostate size to 46% and 41% for prostates > 50 cc and ≤ 80 cc and to 28% and 25% for prostates > 80 cc for MRI versus TRUS and MRI versus PUS, respectively. MRI may be considered clinically interchangeable with TRUS and PUS for prostate sizing at prostate volumes ≤ 50 cc. For larger prostates and when minor changes in prostate size would drastically alter surgical management, cross-sectional imaging should be considered.

Identifiants

pubmed: 34895393

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10889-10899

Auteurs

Samuel Helrich (S)

Department of Urology, UC San Diego Health, University of California, San Diego, San Diego, California, USA.

Wesley Pate (W)

Department of Urology, UC San Diego Health, University of California, San Diego, San Diego, California, USA.

Nishant Garg (N)

Department of Urology, UC San Diego Health, University of California, San Diego, San Diego, California, USA.

Philip Barbosa (P)

Department of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Shaun Wason (S)

Department of Urology, UC San Diego Health, University of California, San Diego, San Diego, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH